Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Recombinant Newcastle disease virus vector containing novel coronavirus double-antigen target sequence combination and corresponding vaccine strain and vaccine

A technology of Newcastle disease virus and coronavirus, which is applied in the field of recombinant Newcastle disease virus vectors and corresponding vaccine strains and vaccines, can solve the problems of restriction, limited immunogenicity, decreased viral load in the lungs of immunized mice, etc., and achieve enhanced immunity The effect of exerting originality and reducing toxic and side effects

Pending Publication Date: 2022-01-04
ZHEJIAN DIFFERENCE BIOLOGICAL TECH CO LTD
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The technical effect that this patented method uses an enzyme called CRBP2 for delivering two different types of molecules - one from another type of bacteria-to create a fusion product containing both proteins – which can protect against diseases caused by certain microorganisms like Newcastle Disease Viruses. This approach has potential benefits over existing methods such as live attenuated influenza vims vectors but it also reduces their harmfulness towards other organism's tissues.

Problems solved by technology

This patented technology describes different types of novel coronaviruses called Corvadesa Virus Type 1(CORVD1) and Novel Coalescent Valley Influenza Virustis (CoVID-19). These two diseases have been identified together due to their similar symptoms: they cause respiratory illness from spreading into indoor environments like restaurants where people come close enough during flu season to transmit these pathogens easily. They also pose threats against other organisms such as bats and rodents. To address this issue, there was proposed a way to increase the amount of anti-corrosion proteins found within the virus's outer shell surface.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Recombinant Newcastle disease virus vector containing novel coronavirus double-antigen target sequence combination and corresponding vaccine strain and vaccine
  • Recombinant Newcastle disease virus vector containing novel coronavirus double-antigen target sequence combination and corresponding vaccine strain and vaccine
  • Recombinant Newcastle disease virus vector containing novel coronavirus double-antigen target sequence combination and corresponding vaccine strain and vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Candidate vaccine strains NDV-S2P-VH-RBD-Fc, NDV-S2P-HSA-deltaRBD-Fc, NDV-S2P-HSA-RBD-Folden, NDV-S2P-M-HSA-RBD-TBSV-F, NDV-S2P -M-HSA-deltaRBD-Fc-F, NDV-S2P-M-HSA-deltaRBD-Ferritin-F, NDV-S2P / GSAS-HSA-deltaRBD-Fc, NDV-S2P / GSAS-HSA-deltaRBD-Folden, NDV -S6P-M-HSA-deltaRBD-Fc-F, NDV-S2P-HAS-scRBD, NDV-S2P-M-scRBD-F, NDV-deltaS2P / F87-M-HSA-deltaRBD-Fc-F, NDV-deltaRBD -NTD-Bann-M-HSA-deltaRBD-Fc-F, NDV-deltaRBD-NTD-Folden-M-HSA-deltaRBD-Fc-F and comparative example vaccine strains NDV-S2P, NDV-deltaS2P / F87, and NDV- Design and construction of VH-RBD-Fc viral vector

[0055] The design of the S protein variant is as follows: the K986P and V987P mutations are performed on the S protein of the original novel coronavirus antigen strain to form the S2P coding sequence, and the R682~R685 amino acids of S2P are mutated to GSAS to form the S2P / GSAS coding sequence, and the S2P is further mutated to F817P , A892P, A899P and A942P mutations to form the S6P coding sequence. At the...

Embodiment 2

[0068] 1. Candidate Vaccine Strain Virus Rescue

[0069] All the recombinant NDV viral vectors constructed in Example 1, and the virus rescue helper plasmids pCI-NP, pCI-P and pCI-L respectively, were transfected into BHK21-T7 cells after the plasmid concentration was measured by Nano drop (disclosed in CN112011521A ). The specific transfection process is as follows: spread BHK21-T7 cells on a six-well plate, and when the cell density reaches 70-80%, take 500 μL Opti-MEM into a 1.5 mL centrifuge tube according to the instructions of Lipofectamin LTX, and then follow the 1:1:1: The ratio of 1 was added to the recombinant NDV virus vector in Example 1, and the pCI-NP, pCI-P and pCI-L helper plasmids, and the total amount of plasmids in each tube was 4 μg, which was used for 1 well. Add 3 μL Plus reagent to each of the above solutions, add 9 μl Lipofectamine LTX after 5 min at room temperature, mix gently, and place at room temperature for 30 min; then take out the BHK21-T7 cell...

Embodiment 3

[0075] In Vitro Evaluation of Recombinant NDV Vector Virus Vaccine Strains

[0076] 1. Determination of HA titer of recombinant vaccine candidate strain

[0077] Dilute each virus vaccine candidate strain of NDV collected to 2 1 Finally, multiple samples of the same virus vaccine strain were inoculated with the allantoic fluid of 9-11-day-old chicken embryos, and the inoculated chicken embryos were sealed with medical tape and cultured at 34 °C. After 72 hours, 100 μl of the allantoic fluid was taken and placed in 96 wells. For V-type hemagglutination plate, dilute the allantoic fluid in 10 gradient series with PBS, and take 50 μl of PBS to set up a negative control at the same time to read the HA titer.

[0078] The results showed that most of the HA titers of initially rescued viruses were 4-8log2, and after passage and adaptation, the vaccine candidate strains all produced higher HA titers, up to 10log2 or more (Table 3).

[0079]

[0080] 2. Antigen expression of reco...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a recombinant Newcastle disease virus vector containing a novel coronavirus double-antigen target sequence combination and a corresponding vaccine strain and a vaccine, and relates to the technical field of biological medicines. According to the invention, an NDV vector, a novel coronavirus S protein gene and an S protein receptor binding domain RBD gene are used as antigen sequences, the S protein gene and the RBD gene are jointly inserted into an NDV genome, and a virus reverse genetics technology is utilized to rescue and obtain the vaccine strain with the infectious NDV virus limiting vector. The vaccine strain can be recognized by respiratory tract cells to generate mucosal immunity and infect the cells, so that the specific immune antibody level is increased. By introducing the double-antigen target, the immunogenicity of the vaccine strain is enhanced, the toxic and side effects of the vaccine strain are reduced, and the immune effect is better than that of a single-target antigen.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Owner ZHEJIAN DIFFERENCE BIOLOGICAL TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products